NSRX קפיטליזציה חשבונאית Nasus Pharma Ltd.

Nasus Pharma Ltd (NSRX) is expanding its portfolio through mass-market nasal sprays targeting allergies and viruses. Government procurement of powders for emergency addiction therapy provides a stable revenue stream. Despite its Israeli origin, exports to the West mitigate geopolitical risks. The current metric stands at 0.00. This NSRX price chart visualizes the market dynamics of this pharmaceutical business.

The stability of Nasus Pharma Ltd (NSRX) is determined by the efficiency of capitalizing developments in intranasal drugs for emergency therapy. Book capitalization, as the difference between all assets and liabilities, measures the real value of equity, allowing for an assessment of the business's internal resilience. By analyzing changes in the company's book capitalization, an investor can determine the extent to which the growth in fundamental value aligns with operational successes during the product line expansion phase.